Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. Based on our previous results, we hypothesize that lesions in patients who receive the combined treatment of pentavalent antimony and imiquimod as a first line therapy will resolve more rapidly and produce less scarring than treatment with pentavalent antimony alone.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
5 Years to 65 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males/Females between 5 and 65 yrs
CL diagnosis confirmed
>4 weeks time disease
no prior anti-leishmanial therapy for CL
negative pregnancy test
informed written consent or parent consent for <18yrs patients
>6 cutaneous lesions
previous exposure to Imiquimod or anti-leish treatment
participation in another protocol within 30 days prior study
other acute or chronic illness / medication that may interfere
significant psychiatric illness
anaphylaxis or severe allergic reaction to proposed drugs